Questions About Clinical Effect Highlight Advisory Committee Uncertainty Over Astellas’ Mirabegron
Executive Summary
Reproductive health drugs advisory committee gives FDA a recommendation for approval for treatment of overactive bladder, but few answers to safety questions, and raises concerns about efficacy.